background image

Paid Clinical Trials Madison

Discover 557 paid clinical trials in Madison, Wisconsin. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Recruiting
PHASE2

Sponsor:

Gilead Sciences

Location:

Madison, Chicago, Springfield, Indianapolisshow 31 more

Code:

NCT03547973

Conditions

Metastatic Urothelial Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Sacituzumab Govitecan-hziy

Pembrolizumab

Cisplatin

Avelumab

Zimberelimab

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

Recruiting
PHASE3

Sponsor:

Priovant Therapeutics, Inc.

Location:

Madison, Rochester, Minneapolis, Carmelshow 33 more

Code:

NCT06431373

Conditions

Uveitis, Posterior

Uveitis, Intermediate

Uveitis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Brepocitinib PO QD

Placebo PO QD

A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

Recruiting
PHASE2

Sponsor:

Fujifilm Pharmaceuticals U.S.A., Inc.

Location:

Madison, Saint Louis, Detroit, Sioux Fallsshow 16 more

Code:

NCT05318573

Conditions

Advanced Urothelial Carcinoma

Advanced Non Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

FF-10832

National Collaborative to Improve Care of Children With Complex Congenital Heart Disease

Recruiting

Sponsor:

Children's Hospital Medical Center, Cincinnati

Location:

Madison, Milwaukee, Chicago, Oak Lawnshow 53 more

Code:

NCT02852031

Conditions

Hypoplastic Left Heart Syndrome (HLHS)

Eligibility Criteria

Sex: All

Age: 0 - 15

Healthy Volunteers: Not accepted

Interventions

Collaborative Learning Network

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Recruiting
PHASE2

Sponsor:

National Cancer Institute (NCI)

Location:

Summit, Oconomowoc, Mukwonago, Waukeshashow 350 more

Code:

NCT03866382

Conditions

Bladder Adenocarcinoma

Bladder Clear Cell Adenocarcinoma

Bladder Mixed Adenocarcinoma

Bladder Neuroendocrine Carcinoma

Bladder Small Cell Neuroendocrine Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Scan

Cabozantinib S-malate

Computed Tomography

Echocardiography

Study of GS-1811 Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

Recruiting
PHASE1

Sponsor:

Gilead Sciences

Location:

Madison, Nashville, Toronto, Dallasshow 6 more

Code:

NCT05007782

Conditions

Advanced Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Denikitug

Zimberelimab

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting
PHASE1
PHASE2

Sponsor:

Stemline Therapeutics, Inc.

Location:

Madison, Chicago, Rochester, Minneapolisshow 37 more

Code:

NCT05563220

Conditions

Breast Cancer

Metastatic Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Elacestrant

Alpelisib

Everolimus

Ribociclib

Palbociclib

Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 Mg) Intravitreal Implants Vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

Recruiting
PHASE3

Sponsor:

Jaeb Center for Health Research

Location:

Madison, Chicago, Iowa City, Rochestershow 12 more

Code:

NCT05844982

Conditions

Radiation Retinopathy

Visual Impairment

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Faricimab

fluocinolone acetonide

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

Recruiting
PHASE3

Sponsor:

Alexion Pharmaceuticals, Inc.

Location:

Madison, Chicago, Rochester, Minneapolisshow 43 more

Code:

NCT06183931

Conditions

Transthyretin Amyloid Cardiomyopathy

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

ALXN2220

Placebo

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Recruiting
PHASE3

Sponsor:

National Cancer Institute (NCI)

Location:

Janesville, Oconomowoc, Mukwonago, Waukeshashow 395 more

Code:

NCT04181060

Conditions

Advanced Lung Non-Squamous Non-Small Cell Carcinoma

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma

Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

Stage IIIB Lung Cancer AJCC v8

Stage IV Lung Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bevacizumab

Biospecimen Collection

Computed Tomography

Echocardiography

Magnetic Resonance Imaging